2,934.80
+3.62%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ngl Fine Chem
Its shares trade on NSE under the ticker NGLFINE.NS. It has been listed since 20 December 1994. In the fiscal year to 31 March 2026, it reported revenue of ₹5.01bn and net income of ₹481.3m. At that date it held total assets of ₹5.45bn and shareholders' equity of ₹3.29bn.
NGL Fine-Chem Ltd. manufactures pharmaceuticals and intermediates for usage in veterinary and human health. The company is headquartered in Mumbai, Maharashtra. The firm caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen, Flunixin Meglumine, and Imidocarb Dipropionate, among others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Dec 1994
- Employees
- 343
- Website
- nglfinechem.com ↗
Leadership
Pay as last reported
- Mr. Rajesh LawandeChief Financial Officer, Whole Time Director, since 2017₹26.5m
- Mrs. Pallavi PednekarCompliance Officer, Company Secretary
- Mr. Rahul NachaneManaging Director, Director₹26.7m
- Mr. Dhananjay MungaleAdditional Non-Executive Director
- Ms. Ajita NachaneNon-Executive Director₹402,500
- Mr. Sudhir DeoAdditional Non-Executive Independent Director
- Ms. Sarala MenonNon-Executive Woman Independent Director₹120,000
- Mr. Jayaram SitaramNon-Executive Independent Director₹422,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- NGL Fine Chem Ltd manufactures APIs for Animal Health with products like Homidium Chloride and Nitroxynil.
- The company produces APIs for Human Health including Nitazoxanide and Atovaquone.
- NGL Fine Chem Ltd offers Intermediates and Specialty Chemicals such as 1,4,7-Trimethyl-1,4,7-Triazacylononane.
Weaknesses
- NGL Fine Chem Ltd has 343 employees which is a small workforce for global manufacturing.
- The company is based in Mumbai, Maharashtra, limiting its operational reach.
- NGL Fine Chem Ltd has been listed since 1994, indicating limited recent growth.
Opportunities
- NGL Fine Chem Ltd can expand its API production for Animal Health in India.
- The company can increase its Human Health API offerings like Nitazoxanide globally.
- NGL Fine Chem Ltd can leverage its Intermediates and Specialty Chemicals for new markets.
Threats
- NGL Fine Chem Ltd faces competition from global pharmaceutical manufacturers.
- The company's reliance on custom manufacturing may lead to unstable demand.
- NGL Fine Chem Ltd's small employee count could hinder scalability during market growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.